Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Depreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Ratios

Neurogene (NGNE) Amortization of Deferred Charges (2019 - 2020)

Neurogene's Amortization of Deferred Charges history spans 2 years, with the latest figure at $253000.0 for Q3 2020.

For Q3 2020, Amortization of Deferred Charges rose 954.17% year-over-year to $253000.0; the TTM value through Sep 2020 reached $808000.0, changed N/A, while the annual FY2014 figure was $320000.0, 2185.71% up from the prior year.
Amortization of Deferred Charges reached $253000.0 in Q3 2020 per NGNE's latest filing, up from $3000.0 in the prior quarter.
In the past five years, Amortization of Deferred Charges ranged from a high of $528000.0 in Q1 2020 to a low of $3000.0 in Q2 2020.